Licensed vaccine
Afluria, Afluria Southern Hemisphere
FDA-licensed vaccine · Seqirus Pty. Ltd. · STN BL 125254
Key facts
| Trade name | Afluria, Afluria Southern Hemisphere |
|---|---|
| Proper name | Influenza Virus Vaccine (Trivalent, Types A and B) |
| Manufacturer | Seqirus Pty. Ltd. |
| Submission tracking number (STN) | BL 125254 |
| FDA product areas | Biologics, Vaccines |
| Recent FDA documents | July 1, 2024 Approval Letter - AFLURIA, March 1, 2024 Approval Letter - AFLURIA, February 1, 2024 Approval Letter - AFLURIA, January 26, 2024 Approval Letter - Afluria Trivalent and Afluria Quadrivalent, June 30, 2023 Approval Letter - Afluria (trivalent) and Afluria Quadrivalent, April 7, 2023 Approval Letter - AFLURIA, July 1, 2022 Approval Letter - Afluria and Afluria Quadrivalent, February 17, 2022 Approval Letter - AFLURIA, February 8, 2021 Approval Letter - Afluria, Package Insert - AFLURIA SOUTHERN HEMISPHERE, August 27, 2020 Approval Letter - Afluria, January 23, 2020 Approval Letter - Afluria and Afluria Quadrivalent |
| FDA page updated | Jul 3, 2024 |
| FDA product page | fda.gov |
At a glance
- 10–99 FDA approval letters
- 10–99 Supporting documents
- 1–9 Product information documents
- Yes Document full text searchable in Orca1
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA-licensed vaccines
The FDA's CBER licenses vaccines for use in the United States. Each product page links the approval letters, package inserts and supporting documents for that vaccine.
Source: U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), Vaccines Licensed for Use in the United States · Source date: